Interferon Alfa-2a [Recombinant]: Brands, Price & Uses in Bangladesh

Interferon Alfa-2a [Recombinant] is a biologic response modifier used in a range of oncologic and viral conditions. Its use is classified below by strength of evidence.

Established / approved uses

• Hairy cell leukemia in adult patients.
• Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive, chronic phase, in adult patients (often used historically before or in combination with tyrosine kinase inhibitors).
• AIDS-related Kaposi's sarcoma in adult patients with adequate CD4 counts and without systemic opportunistic infection.

Guideline-supported / historically approved uses (largely superseded)

• Chronic hepatitis B infection, as an option in select patients, generally superseded by nucleos(t)ide analogues (entecavir, tenofovir).
• Chronic hepatitis C infection, historically used alone or with ribavirin; largely replaced today by direct-acting antivirals (DAAs), and now reserved for limited settings where DAAs are unavailable or unsuitable.

Other malignancies (per specific product labeling / combination regimens)

• Certain other malignancies such as follicular non-Hodgkin's lymphoma and select renal cell carcinoma regimens, typically as adjunct or combination therapy per specialist protocols.

Use of Interferon Alfa-2a [Recombinant] for any indication should be initiated and supervised by a physician experienced in the relevant disease area.

Dosage of Interferon Alfa-2a [Recombinant] is individualized by indication, patient tolerance, and response, and must be adjusted or interrupted for significant toxicity. The table below summarizes typical adult regimens; pediatric use is not established for these indications (see Pediatric Uses).

Dose modification or temporary discontinuation is required for severe hematologic, hepatic, cardiac, or neuropsychiatric toxicity. Renal or hepatic impairment warrants closer monitoring; formal dose-adjustment tables are not well established, and lower starting doses with close monitoring are advised.

Adverse effects of Interferon Alfa-2a [Recombinant] are dose- and duration-dependent and require ongoing monitoring.

Very common

• Flu-like syndrome: fever, chills, myalgia, headache, fatigue (especially with initial doses).
• Anorexia, nausea, and weight loss.
• Injection site reactions.
• Alopecia (usually reversible).

Serious / warranting close monitoring

• Bone marrow suppression (neutropenia, thrombocytopenia, anemia).
• Neuropsychiatric effects, including depression, irritability, and suicidal ideation/behavior.
• Autoimmune disorders, including thyroid dysfunction (hypo- or hyperthyroidism).
• Hepatotoxicity and, rarely, hepatic decompensation.
• Cardiovascular effects (arrhythmia, hypotension, rarely myocardial infarction) in susceptible patients.
• Ophthalmologic effects (retinopathy, rarely vision loss).